As­traZeneca, Can­cer Re­search UK set up ge­nomics hub to fight up­hill bat­tle against can­cer

In the wake of two big fail­ures for their check­point in­hibitor/CT­LA-4 com­bo, As­traZeneca $AZN is brush­ing its Brex­it fear aside and pour­ing its R&D heft in­to a new cen­ter in part­ner­ship with Can­cer Re­search UK, de­signed to har­ness the pow­er of ge­nomics to de­vel­op per­son­al­ized can­cer drugs.

The fa­cil­i­ty, which will be housed at the Uni­ver­si­ty of Cam­bridge, is hop­ing to tap in­to the po­ten­tial of func­tion­al ge­nomics, in par­tic­u­lar the gene edit­ing tool CRISPR, to bet­ter un­der­stand can­cer bi­ol­o­gy and ge­net­ic dri­vers of drug re­sis­tance, in a bid to bring treat­ments to pa­tients faster.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER